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Abstract
A novel, rapid and sensitive liquid chromatography-tandemmass spectrometric (LC-MS/
MS) method was developed and validated for the evaluation of exemestane pharmacokinet-
ics and its metabolites, 17β-dihydroexemestane (active metabolite) and 17β-dihydroexe-
mestane-17-O-β-D-glucuronide (inactive metabolite) in human plasma. Their respective D3
isotopes were used as internal standards. Chromatographic separation of analytes was
achieved using Thermo Fisher BDS Hypersil C18 analytic HPLC column (100 × 2.1 mm,
5 μm). The mobile phase was delivered at a rate of 0.5 mL/min by gradient elution with 0.1
% aqueous formic acid and acetonitrile. The column effluents were detected by API 4000 tri-
ple quadrupole mass spectrometer using electrospray ionisation (ESI) and monitored by
multiple reaction monitoring (MRM) in positive mode. Mass transitions 297> 121m/z, 300
> 121m/z, 299> 135m/z, 302> 135m/z, 475> 281m/z, and 478> 284m/z were moni-
tored for exemestane, exemestane-d3, 17β-dihydroexemestane, 17β-dihydroexemestane-
d3, 17β-dihydroexemestane-17-O-β-D-glucuronide, and 17β-dihydroexemestane-17-O-β-
D-glucuronide-d3 respectively. The assay demonstrated linear ranges of 0.4 – 40.0 ng/mL,
for exemestane; and 0.2 – 15.0 ng/mL, for 17β-dihydroexemestane and 17β-dihydroexe-
mestane-17-O-β-D-glucuronide, with coefficient of determination (r2) of> 0.998. The preci-
sion (coefficient of variation) were10.7%, 7.7% and 9.5% and the accuracies ranged from
88.8 to 103.1% for exemestane, 98.5 to 106.1% for 17β-dihydroexemestane and 92.0 to
103.2% for 17β-dihydroexemestane-17-O-β-D-glucuronide. The method was successfully
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applied to a pharmacokinetics/dynamics study in breast cancer patients receiving exemes-
tane 25mg daily orally. For a representative patient, 20.7% of exemestane in plasma was
converted into 17β-dihydroexemestane and 29.0% of 17β-dihydroexemestane was inacti-
vated as 17β-dihydroexemestane-17-O-β-D-glucuronide 24 hours after ingestion of exe-
mestane, suggesting that altered 17-dihydroexemestane glucuronidation may play an
important role in determining effect of exemestane against breast cancer cells.
Introduction
Breast cancer has remained the most common cancer among females in Singapore over the last
forty years.[1] Currently, the role of exemstane (Exe) in breast cancer treatment is evolving;
traditionally used as an adjuvant medication for hormone receptor positive breast cancer, new
trials have investigated its role as adjuvant medication in metastatic cancer and preventive
medication in high-risk women.[2–6] In the adjuvant setting, Exe, similar to the other third-
generation compounds, revealed improved relapse-free survival compared to tamoxifen mono-
therapy when administered as sequential therapy.[7] Exe is the first steroidal aromatase inhibi-
tor (AI) which inhibits in vivo formation of oestrogens (estrone and estradiol), thereby
reducing stimulation for breast cancer cell proliferation.[8] Variability in response and side ef-
fect profile has been observed in patients in many AI clinical trials and the underlying mecha-
nism remains undefined.[9–13] Recently, the major metabolic pathway of Exe has been
delineated; as a reduction of double bond in 17 keto group via aldo-keto reductase (AKR) to
form 17β-dihydroexemestane (17DhExe) is a major pathway for exemestane phase I metabo-
lism. [14] In addition, 17DhExe has been reported to be an active metabolite which is subse-
quently inactivated by glucuronidation to 17β-dihydroexemestane-17-O-β-D-glucuronide
(Exe17Oglu). [15, 16] Inactivation of 17DhExe is catalysed by the enzyme UDP-gluconoryl-
transferase 2B17 (UGT2B17). Exemestane’s major metabolism pathway is summarized in
Fig. 1. It has also been identified that 60–70% of Asians suffer from homozygous gene deletion
of UGT2B17, which can result in reduced glucuronidation of 17DhExe and increased exposure
to this active metabolite. [16] Therefore, simultaneous quantification of Exe, 17DhExe, and
Exe17Oglu can aid in determination of the impact of homozygous UGT2B17 gene deletion on
the in vivometabolic profile of Exe. [17]
To date, two reported analytical methods have been developed and validated for determina-
tion of Exe and 17DhExe; one is a HPLC-UV assay with low limit of quantification (LLOQ) of
10 ng/mL for both parental drug and 17DhExe [18] and the other is a LC-MS/MS method with
Fig 1. Exemestane major metabolism pathway.
doi:10.1371/journal.pone.0118553.g001
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LLOQ of 0.2 ng/ml for Exe and 0.1 ng/ml for 17DhExe.[19] Compared to HPLC-UV method,
the LC-MSMS method demonstrated superior sensitivity and specificity which are critical to
accurately quantify analytes of interest. Nevertheless, no analytical method has been estab-
lished to concurrently quantify Exe and its two key metabolites (17DhExe and Exe17Oglu)
within one chromatographic run. This is a major research gap to determine the influence of
UGT2B17 variants on the glucuronidation of 17DhExe in human plasma samples. In order to
support a clinical trial of Exe in breast cancer patients in Singapore National University Hospi-
tal (NUH), a simple, novel and sensitive LC-MS/MS method was developed for determination
of plasma concentrations of these three compounds simultaneously. The well-validated meth-
od has been successfully applied to determine the plasma concentrations of Exe and two im-
portant metabolites in clinical plasma samples of breast cancer patients.
Experimental
Chemicals and Reagents
Exemestane, 17β-hydroxyexemestane, and 17β-hydroxyexemestane-17-O-β-D-glucuronide,
the reference standards, were purchased from Toronto Research Chemicals Inc. (North York,
Ontario, Canada). Exemestane-d3, 17β-hydroxyexemestane-d3 and 17β-hydroxyexemestane-
d3–17-O-β-D-glucuronide, the stable isotope-labelled internal standards (IS), were also pur-
chased from Toronto Research Chemicals Inc. (North York, Ontario, Canada).
Methanol, acetonitrile and formic acid (100%, v/v) were purchased fromMerck (Darmstadt,
Germany). Milli-Q water fromMilli-Q Plus system (Millipore, Milford, MA, USA) was used
throughout the study.
Drug-free blank human plasma was obtained from healthy donors from the National Uni-
versity Hospital (NUH), Singapore.
Chromatographic and Mass Spectrometric Conditions
LC-MS/MS analysis was performed using an API 4000 triple quadrupole mass spectrometer
(Applied Biosystems, MDS SCIEX, Ontario, Canada). The HPLC system was composed of Agi-
lent 1100 series gradient pump, degasser, autosampler and column oven (Agilent Technologies,
Germany). The data was acquired and processed using Analyst software (Version 1.4.2, Ap-
plied Biosystems, MDS SCIEX, Ontario, Canada).
The chromatographic separation of analytes from endogenous compounds was performed
on a BDS Hypersil C18 column (100 × 2.1 mm, 5 μm, Thermo Fisher Scientific, Waltham,
Massachusetts, United States), which was preceded by a SecurityGuard cartridge (4.0 × 3.0
mm, Phenomenex, CA, United States). The column and the autosampler were both maintained
at 24°C.
The mass spectrometer was equipped with an electrospray ionisation source and it was op-
erated in the positive ion detection mode in the multiple reaction monitoring (MRM).
Preparation of Stock Solutions, Calibration and Quality Control
Standards
Stock solutions of Exe, Exe-d3, 17DhExe, 17DhExe-d3, Exe17Oglu and Exe17Oglu-d3 were pre-
pared with methanol at 1.0 mg/mL. Seven standard working solutions of Exe were prepared by
serial dilution with methanol to achieve concentrations of 4, 10, 20, 40, 100, 200 and 400 ng/mL.
Similarly, seven standard working solutions of 17DhExe and Exe17Oglu were prepared sepa-
rately by serial dilution with methanol to achieve concentrations of 2, 5, 10, 20, 40, 100, and
200 ng/mL. A working solution of IS was prepared at 100 ng/mL, for Exe-d3, 17DhExe-d3, and
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Exe17Oglu-d3. Three quality control (QC) working solutions of Exe were prepared by serial di-
lution with methanol to achieve concentrations of 30, 75, and 250 ng/mL. Similarly, three QC
working solutions of 17DhExe and Exe17Oglu were prepared separately by serial dilution with
methanol to achieve concentrations of 15, 40, and 100 ng/mL. All stock and working solutions
were stored at 4°C.
Calibrator and Quality Control Sample Preparation
Five μL of each standard working solution and 10 μL of the IS working solution were placed
into 1.5 mL polypropylene (PP) centrifuge tube. An aliquot of human plasma (50 μL) was
added, and the PP tube was vortexed for 30 s. Proteins were precipitated by addition of 150 uL
of acetonitrile subsequently and the PP tube was vortexed for another 30 s. Next, the PP tube
was centrifuged at 35,000 × g for 10 min at 4°C. Thereafter, 150 μL of the supernatant was
transferred to a second 1.5 mL PP tube and the supernatant dried by concentrator plus (Eppen-
dorf) for 60 min at 45°C. The dried residue was reconstituted with 50 μL of acetonitrile—0.1%
formic acid mixture (25:75, v/v) and vortexed for 30 s. After that, the tubes were centrifuged at
35,000 × g for 10 min at 4°C. Forty microliters of the resulting supernatant was transferred to a
250 μL glass insert in an autosampler vial. A volume of 30 μL was injected per run for quantita-
tive analysis by LC-MS/MS.
Construction of Standard Calibration Curve
The standard calibration curves were constructed using six concentrations. The calibrators
were prepared at the following concentrations: 0.4, 1.0, 2.0, 5.0, 10.0, 20.0, and 40.0 ng/mL for
Exe; and 0.2, 0.5, 1.0, 2.0, 5.0, 7.5, and 15.0 ng/mL, for 17DhExe and Exe17Oglu. The standard
calibration curves of Exe, 17DhExe, and Exe17Oglu were generated using the peak area ratios
of Exe to Exe-d3, 17DhExe to 17DhExe-d3, and Exe17Oglu to Exe17Oglu-d3 respectively.
Bioanalytical Method Validation
A full method validation was performed according to guidelines for bioanalytical method vali-
dation by the United States Food and Drug Administration. [20]
Selectivity, Carry-over and Linearity
Six different sources of blank human plasma were tested for interference in the selectivity test.
Blank wash samples were analysed right after the highest concentration calibration stan-
dards, for a total of six times, in the carry-over test.
The coefficients of determination (r2) of the standard calibration curves were used in the
linearity test.
Accuracy and Precision
The accuracy and precision were validated by analysing QC samples at nominal concentrations
of 3.0, 7.5, 25.0 ng/mL for Exe; and 1.5, 4.0, 10.0 ng/mL for 17DhExe and Exe17Oglu. Intra-day
accuracy and precision were determined by performing a standard calibration curve with QC
samples in quintuplicate in a single run. Inter-day accuracy and precision were determined by
performing standard calibration curves with QC samples on five separate days. Accuracy was
calculated as a percentage of the mean value measured over the nominal value at each concen-
tration; precision was expressed in terms of coefficient of variation (CV), defined as percentage
of the standard deviation divided by the mean.
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Matrix Effect
The matrix effect was validated by analysing the ratios of analytes and IS peak areas in the
matrix-based tubes to those in the reference tubes. The validation was carried out on QC
samples in quadruplicate at each concentration.
For the matrix-based tube, 50 μL of blank human plasma was placed in a 1.5 mL PP tube.
150 μL of acetonitrile was added subsequently and the PP tube was vortexed for another 30 s.
The PP tube was centrifuged at 35,000 × g for 10 min at 4°C. Thereafter, 150 μL of the super-
natant was transferred to a second 1.5 mL PP tube. Five microliters of each QC working solu-
tion and 10 μL of the IS working solution were added, and the PP tube was vortexed for 30 s.
The mixture was subsequently dried. The dried mixture was reconstituted with 50 μL of ace-
tonitrile—0.1% formic acid mixture (25:75, v/v) and vortexed for 30 s. The reconstituted mix-
ture was centrifuged at 35,000 × g for 10 min at 4°C. 40 μL of the reconstituted mixture was
transferred to a 250 μL glass insert in an autosampler vial for analysis.
For the reference tube, the procedure was repeated with 50 μL of milliQ water replacing the
blank human plasma.
Recovery
The recovery was investigated by analysing the ratios of analytes and IS peak areas in the tube
spiked before extraction to those in the tube spiked after extraction. The validation was carried
out on QC samples in quadruplicate at each concentration.
For the tube spiked before extraction, the steps were carried out as in Section of Calibrator
and Quality Control Sample Preparation.
For the tube spiked after extraction, the steps were carried out as in Section of Matrix Effect
for the matrix-based tube.
Stability
Stability of the analytes in human plasma was determined using QC samples in triplicates at
each concentration.
(a) Short-term Temperature Stability
Intervals of 4, 8, and 24 hours were selected for stability testing. Nine aliquots of each QC
concentration were prepared in human plasma and kept on the bench-top. Three aliquots of
each QC concentration were taken at each time interval after 4, 8, and 24 hours. Sample prepa-
ration, as stipulated in Section 2.4 with the exception of spiking with the standard working so-
lutions, was then carried out to analyse the samples.
(b) Freeze-thaw Stability
Three, six, and nine freeze-thaw cycles were selected for stability testing. For each set (i.e.
three, six, and nine freeze-thaw cycles), three aliquots of each QC concentration were prepared
in human plasma, stored at -80°C until completely frozen, and thawed unassisted at room tem-
perature. Upon completion of thawing, the samples were refrozen at -80°C. The freeze-thaw
cycle was then repeated for a total of two, five, and eight times respectively to execute three, six,
and nine freeze-thaw cycles. Sample preparation, as stipulated in Section of Calibrator and
Quality Control Sample Preparation with the exception of spiking with the standard working
solutions, was then carried out to analyse the samples.
Dilution factor
In the quantification of patient samples, a few samples were found to exceed the maximum cal-
ibrated concentration of Exe (40.0 ng/mL). Dilution was carried out with blank human plasma
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by a factor of three before sample preparation. Actual concentrations of the patient samples
were then back-calculated by multiplication of the quantified concentrations by three. Valida-
tion of the dilution procedure was carried out using spiked plasma samples of Exe at 50.0, 60.0,
and 70.0 ng/mL in quadruplicates. No extrapolation of the calibration was performed to quan-
tify Exe at concentrations above 40.0 ng/mL.
Application in human plasma
Human plasma samples were obtained from breast cancer patients with post-menopausal, hor-
mone receptor positive advanced breast cancer enrolled in a pharmacokinetics/dynamics study
at National University Hospital, Singapore. This clinical trial has been approved by the Nation-
al Healthcare Group Domain Specific Review Board (DSRB), the Institutional Review Board
(IRB) of National University Hospital. Written informed consent was obtained. It was docu-
mented in a DSRB-approved written informed consent form and signed by the subject or sub-
ject’s legally authorized representative. An oral dose of exemestane (25 mg) was administered
daily, starting from day 1. Plasma samples were collected on day 29 before dosing, and 0.5, 1, 2,
4, 6, 8 and 24 hours after exemestane ingestion.
The samples were stored frozen at -80°C and thawed unassisted at room temperature prior
to analysis. Sample preparative procedure was carried out as stipulated in Calibrator and Quali-
ty Control Sample Preparation, with the exception of spiking of the standard working solu-
tions. Quantification of patient samples was derived and calculated using interpolation within
the standard calibration curve. The area under the curve (AUC) in a plot of concentrations of
Exe and its metabolites were calculated through non-compartmental analysis using pharmaco-
kinetic software (WinNonlin 5.3.).
Results and Discussion
LC-MS/MS optimization
Mass spectrometric parameters were optimised and the product ion mass spectra of each ana-
lyte under optimised conditions were as follows. Based on Fig. 2, mass transitions 297>
121m/z and 300> 121m/z were monitored for Exe (C20H24O2, molecular weight: 296.40) and
Exe-d3 (C20H21O2D3, molecular weight: 299.43) respectively. Mass transitions 299> 135m/z
and 302> 135m/z were monitored for 17DhExe (C20H26O2, molecular weight: 298.43) and
17DhExe-d3 (C20H23O2D3, molecular weight: 301.44) respectively. Mass transitions 475> 281
m/z and 478> 284m/z were monitored for Exe17Oglu (C26H34O8, molecular weight: 474.54)
and Exe17Oglu-d3 (C26H31O8D3, molecular weight: 477.56) respectively. The desolvation tem-
perature was set at 500°C, the electrospray ionisation source 5500 V, and the optimised en-
trance potential 10 V. The optimised declustering potentials were set at 61 V for Exe, Exe-d3,
17DhExe, and 17DhExe-d3; and 81 V, for Exe17Oglu and Exe17Oglu-d3. The optimised colli-
sion energies were set at 33 V for Exe and Exe-d3; 29 V for 17DhExe and 17DhExe-d3; 23 V
for Exe17Oglu and Exe17Oglu-d3. The optimised collision cell exit potentials were set at 8 V
for Exe, Exe-d3, 17DhExe, and 17DhExe-d3; 14 V for Exe17Oglu and Exe17Oglu-
d3 respectively.
A total of three reversed-phase HPLC columns were investigated for chromatographic sepa-
ration of analytes from endogeneous interferences and among analytes. BDS Hypersil C18 col-
umn was chosen as the final chromatographic column due to the successful baseline separation
of analytes, reduced run-time and symmetrical chromatographic peaks achieved.
Acetonitrile, methanol and acetonitrile—methanol mixture (70:30, v/v) were investigated as
organic solvents for HPLC mobile phase. Acetonitrile was chosen as the final organic solvent
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due to the reduced run-time, baseline separation among the peaks of analytes and from the
endogenous substances.
Formic acid 0.1% and acetic acid 0.1% were investigated as aqueous solvents for HPLC mo-
bile phase. Formic acid 0.1% was chosen as the final aqueous solvent due to the increased sensi-
tivity and better peak shape achieved.
Isocratic elution and gradient elution were investigated as programmes for chromatographic
separation. Gradient elution was chosen as the final chromatographic programme due to the
successful baseline separation of analytes, reduced endogeneous interference, and sharpened
analyte peaks. In addition, Exe and 17DhExe are much more hydrophobic than Exe17Oglu.
Hence, only the gradient elution can analyze Exe and its metabolites simultaneously within a
short run time. The mobile phase was composed of 0.1% aqueous formic acid (Phase A) and
acetonitrile (Phase B). The following gradient programme was used: 0.00–0.10 min: 25% B,
0.10–0.20 min: 25! 62% B (linear), 0.20–1.60 min: 62% B, 1.60–1.65 min: 62! 25% B
Fig 2. Product ion mass spectra of (a) Exe (b) 17DhExe and (c) Exe17Oglu.
doi:10.1371/journal.pone.0118553.g002
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(linear), 1.65–6.00 min: 25% B. The flow rate was set at 0.5 mL/min. The resulting chromato-
grams of 3 analytes at their low limit of quantitation are shown in Fig. 3.
Extraction Protocol Optimisation
Extraction and pre-concentration methods were optimised to improve the recovery and in-
crease the sensitivity of the assay.
Solid-phase extraction, liquid-liquid extraction and direct protein precipitation were carried
out to investigate the optimal method for sample extraction.
HLB, WCX, WAX and LC-CN solid phases were investigated for solid-phase extraction. All
four solid phases were found to be unable to retain Exe17Oglu and thus unsuitable for
sample extraction.
Ethanol—ethyl acetate mixture (4:1, v/v) and methyl-tert-butyl-ether were investigated as
organic solvents for liquid-liquid extraction. Both solvent systems were found to be unable to
extract Exe17Oglu and thus unsuitable for sample extraction as well.
Due to the different polarities of the analytes of interest, with Exe and 17DhExe being non-
polar compounds, and Exe17Oglu being a highly polar substance, solid-phase extraction and
liquid-liquid extraction methods were unable to extract all three analytes to a reasonable recov-
ery. This may be due to the intrinsic nature of these extraction methods, which take advantage
of the different polarities between compounds and interfering substances for separation from
endogeneous interferences.
Acetonitrile in two volumes and three volumes were investigated as organic solvent for di-
rect protein precipitation. Acetonitrile in three volumes was chosen as the final sample prepa-
ration method due to the sufficient sample clean-up and less matrix effect. Furthermore, no
interfering peaks were observed in the chromatogram, which validated the use of acetonitrile
in three volumes for protein precipitation.
Fig 3. Representative chromatograms of (a) Exe (b) 17DhExe and (c) Exe17Oglu at LLOQ and (a) Exe-d3, (b) DhExe-d3 as well as Exe17Oglu at
100 ng/mL as internal standards.
doi:10.1371/journal.pone.0118553.g003
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Method validation
Selectivity, Carry-over and Linearity. Selectivity for the analytes was shown by peak iden-
tification of analytes without interferences at their respective lower limits of quantification
(LLOQ, 0.4 ng/mL, for Exe; and 0.2 ng/mL, both for 17DhExe and 17DhExe-17Oglu). A chro-
matogram of the standard plasma spiked with three analytes at the concentrations of LLOQ is
shown in Fig. 3.
No carry-over effect was shown as the injection of wash after that of plasma with highest
spiked concentration showed no peaks.
Linearity of the calibration curves were shown by the high r2 of> 0.998, which implied a
strong correlation between the peak area ratio and concentration of each analyte in their linear
ranges of 0.4–40.0 ng/mL, for exemestane; and 0.2–15.0 ng/mL, for 17β-dihydroexemestane
and 17β-dihydroexemestane-17-O-β-D-glucuronide.
Accuracy and Precision. Results of intra-day and inter-day tests are shown in Table 1.
The precision (coefficient of variation) were10.7%, 7.7% and 9.5% and the accuracies ranged
from 88.8 to 103.1% for exemestane, 98.5 to 106.1% for 17β-dihydroexemestane and 92.0 to
103.2 for 17β-dihydroexemestane-17-O-β-D-glucuronide. Taken together, both intra-day and
inter-day accuracy and precision were within 15%, as stipulated by the FDA guidelines.
Matrix Effect. Matrix effect was demonstrated to be significant for Exe, 17DhExe, and
Exe17Oglu. Ion suppression was significant, especially for Exe17Oglu. However, with the use
of stable isotope-labelled IS for all three analytes, the relative matrix effect was demonstrated to
be close to 100%, permitting correction of the matrix effect. Results of matrix effect tests are
shown in Table 2.
Recovery. The relative recoveries of Exe, Exe-d3, 17DhExe, and 17DhExe-d3 were demon-
strated to be greater than 98%. This showed that the extraction protocol was efficient and com-
plete for these four compounds. Even though the relative recoveries of Exe17Oglu and
Exe17Oglu-d3 were found to be about 85%, the recoveries of Exe17Oglu and its IS were consis-
tent and similar, allowing adjustment of the low recovery and fulfilling the FDA validation
guidelines. Results of recovery tests are shown in Table 3.
Table 1. Intra-run and inter-run concentrations, accuracy and precision of QC samples for Exe, 17DhExe and Exe17Oglu.
Analyte Nominal Conc. (ng/mL) Calculated Conc. (ng/mL) *Accuracy (%) #Precision (%)
Intra-day Inter-day Intra-day Inter-day Intra-day Inter-day
Exe 3.0 2.94 ± 0.12 3.00 ± 0.26 97.9 100.1 4.02 8.81
7.5 6.66 ± 0.14 7.37 ± 0.79 88.8 98.3 2.13 10.7
25.0 23.72 ± 1.52 25.78 ± 2.41 94.9 103.1 6.41 9.34
17DhExe 1.5 1.57 ± 0.09 1.52 ± 0.10 104.5 101.3 5.69 6.22
4.0 4.24 ± 0.31 4.09 ± 0.20 106.1 102.3 7.38 4.89
10.0 10.42 ± 0.75 9.85 ± 0.76 104.2 98.5 7.24 7.68
Exe17Oglu 1.5 1.49 ± 0.11 1.55 ± 0.08 99.3 103.2 7.38 5.58
4.0 3.83 ± 0.37 4.06 ± 0.31 95.8 101.5 9.53 8.02
10.0 9.20 ± 0.49 9.72 ± 0.85 92.0 97.2 5.37 8.69
*Expressed as percentage of the mean value (n = 4) measured over the nominal value
#Expressed as percentage of the standard deviation divided by the mean
doi:10.1371/journal.pone.0118553.t001
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Table 2. Matrix Effect of QC Samples for Exe, 17DhExe and Exe17Oglu and their internal standards.
Analyte Nominal Conc. (ng/mL) *Matrix Effect (%) *Matrix Effect of IS at 10 ng/mL (%) #Relative Matrix Effect (%)
Exe 3.0 64.2 ± 11.8 62.2 ± 7.18 103.2
7.5 62.3 ± 7.65 64.3 ± 9.03 96.9
25.0 61.4 ± 10.6 60.1 ± 4.35 102.2
17DhExe 1.5 53.3 ± 5.31 54.4 ± 9.83 98.0
4.0 52.1 ± 3.13 53.0 ±8.76 98.3
10.0 53.4 ± 4.41 55.3 ± 6.54 96.6
Exe17Oglu 1.5 33.1 ± 4.88 31.2 ± 5.02 106.1
4.0 34.1 ± 3.16 35.0 ± 3.69 97.4
10.0 35.3 ± 2.65 35.2 ± 2.84 100.3
*Expressed as average percentage (n = 4) of peak area of analyte in matrix-based tube with that in reference tube
#Expressed as ratio of matrix effect on compound to that of IS
doi:10.1371/journal.pone.0118553.t002
Table 3. Recovery of QC Samples for Exe, Exe-d3, 17DhExe, 17DhExe-d3, Exe17Oglu, and Exe17Oglu-d3.













*Expressed as mean percentage (n = 4) of peak area of analyte in the tube spiked before extraction to that in the tube spiked after extraction
doi:10.1371/journal.pone.0118553.t003
Table 4. Short-term and freeze-thaw stability of QC samples of Exe, 17DhExe and Exe17Oglu.
Stability*
Analyte Nominal Conc. Short-term (hours) Freeze-thaw (cycles)
ng/mL 4 8 24 3 6 9
3.0 106.8 108.7 88.2 103.8 113.9 112.7
Exe 7.5 114.3 108.8 105.1 114.0 112.4 110.9
25.0 112.8 109.6 95.1 109.6 112.0 113.1
1.5 111.1 112.0 109.6 106.0 108.0 110.7
17DhExe 4.0 111.8 109.6 111.8 108.7 110.1 112.5
10.0 109.7 112.0 112.7 108.0 109.7 104.7
1.5 100.7 106.0 95.6 94.9 100.2 107.6
Exe17Oglu 4.0 101.7 105.7 103.5 96.6 107.3 110.7
10.0 107.7 109.7 107.3 106.4 101.9 110.0
*Expressed as mean percentage (n = 3) of quantiﬁed concentration to nominal concentration
doi:10.1371/journal.pone.0118553.t004
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Stability. Stabilities of Exe, 17DhExe, and Exe17Oglu were demonstrated to be with-
in ± 15% of nominal concentrations. This indicated that the analytes of interest was stable in
human plasma during short-term bench-top storage and freeze-thaw cycles. Results of stability
tests are shown in Table 4.
Dilution Factor. Due to the presence of patient samples which exceed the maximum cali-
brated concentration of Exe (40.0 ng/mL), dilution was carried out with blank human plasma
by a factor of three before sample preparation. Accuracy and precision of the dilution proce-
dure prior to sample preparation were within 10%, thus ensuring reliability of the procedure.
Results of accuracy and precision of the dilution procedure are shown in Table 5.
Table 5. Accuracy and Precision of Dilution Procedure for Exe.
Nominal Concentration (ng/mL) Dilution Factor Quantiﬁed Concentration(Mean ± S.D., ng/mL) *Accuracy (%) #Precision (%)
50.0 3 46.90 ± 1.86 93.8 3.97
60.0 3 58.43 ± 1.02 97.4 1.75
70.0 3 73.88 ± 2.28 105.5 3.09
*Expressed as mean percentage (n = 4) of the mean value measured over the nominal value
#Expressed as percentage of the standard deviation divided by the mean
doi:10.1371/journal.pone.0118553.t005
Fig 4. Mean concentrations of a) Exe (b) 17DhExe and (c) Exe17Oglu in plasma samples of one representative breast cancer patient.
doi:10.1371/journal.pone.0118553.g004
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Application of Validated LC-MS/MS Method
The developed method for the simultaneous quantification of Exe and its metabolites,
17DhExe, and Exe17Oglu was successfully applied in a pharmacokinetics/dynamics study, in
which all the plasma samples taken from one typical patient were quantified for the concentra-
tions of Exe, 17DhExe, and Exe17Oglu over 24 hours after exemestane ingestion at dose of 25
mg. Pharmacokinetic profiles were plotted and are shown in Fig. 4 in which the time-concen-
tration profiles of Exe, 17DhExe and Exe17Oglu were well described with 24 hours. The maxi-
mum concentrations of Exe, 17DhExe and Exe17Oglu were observed as 38.5, 3.6 and 1.5
ng/mL respectively at 2 hours after exemestane ingestion. The AUC calculated using WinNon-
lin software with non-compartmental analysis were 129.6, 24.2 and 15.7 ng/mL for Exe,
17DhExe, and Exe17Oglu respectively.
Conclusions
A simple, novel and specific LC-MS/MS assay for the quantification of Exe and its two main
metabolites was developed and fully validated according to the FDA guidelines. This method
offers a significant advantage over previously reported methods due to its ability to quantify
Exe17Oglu as well. Excellent linearity was demonstrated within the ranges of 1.0–40.0ng/mL
for Exe and 0.5–15.0ng/mL for 17DhExe and Exe17Oglu. Accuracy and precision (CV) were
well within FDA guidelines of< 15%. The method was also successfully utilised for the quanti-
fication of Exe and its two main metabolites in human plasma in a pharmacokinetics/dynamics
study. For a representative patient, 20.7% of exemestane in plasma was converted into 17β-
dihydroexemestane and 29.0% of 17β-dihydroexemestane was inactivated as 17β-dihydroexe-
mestane-17-O-β-D-glucuronide 24 hours after ingestion of exemestane, suggesting that altered
17-dihydroexemestane glucuronidation may play an important role in determining effect of
exemestane against breast cancer cells due to genetic difference of UGT2B17 among breast
cancer patients.
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